Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$45.00 USD
-0.92 (-2.00%)
Updated May 17, 2024 04:00 PM ET
After-Market: $45.08 +0.08 (0.18%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Earnings News For CRBP
-
Corbus Pharmaceuticals: Q1 Earnings Snapshot
-
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q1 Earnings Snapshot
-
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
-
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?